Dr Alison Layton

Dr Alison Layton is a Consultant Dermatologist and Associate Medical Director for Research and Development. Her interests include androgen mediated disorders, skin cancers, and rosacea.

  • Name

    Dr Alison Layton

  • Job title

    Consultant Dermatologist and Associate Medical Director for Research and Development

  • GMC Number

    2718699

  • Qualifications

    MBChB - Sheffield University, 1982
    MRCP UK – 1987
    Vocational Training Certificate – 1988
    Family Planning Certificate – 1988
    FRCP UK - 1999

  • Services

    Dermatology

  • Medical Interests

    Androgen mediated disorders (acne, polycystic ovary syndrome)
    Rosacea
    Skin cancers
    Wound care

Dr Alison Layton

I qualified in medicine at the University of Sheffield before training as a general practitioner and in general medicine. I then specialised in dermatology at Leeds Teaching Hospitals before taking up my appointment as Consultant Dermatologist at Harrogate and District NHS Foundation Trust.

Since my appointment I have introduced a novel, fully comprehensive dermatology service which has expanded considerably over the last few years. Within the Dermatology Department I run a dedicated service related to my areas of expertise, including acne and polycystic ovary syndrome. This attracts referrals from across the UK and is used as an educational resource for staff training in dermatology. I also provide fast track clinics for skin cancer as well as general dermatology.

I am very interested in research as a means of improving health care for all. I lead on research and development within the Trust and have conducted many clinical trials embracing inflammatory skin disorders, dermato-oncology and wound care.

I am an Honorary Senior Clinical Lecturer at Hull York Medical School and clinical affiliate to the Centre for Immunology and Infection, University of York. As one of two Clinical Directors for the National Institute of Health Research, Yorkshire and Humber Clinical Research Network I am committed to ensuring equitable access for patients to take part in high quality studies across the whole region and in all clinical specialties as a means of improving outcomes and contributing to the health of our population.